XDR-TB, what is it; how is it treated; and why is therapeutic failure so high?

Recent Patents on Anti-Infective Drug Discovery

Volumn 6, Issue 2, 2011, Pages 77-83

  Gillespie, Stephen H ^a   Singh, Kasha ^b  

^a UNIVERSITY OF ST ANDREWS   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Drug resistance; Extensively drug resistant tuberculosis; Multi drug resistant tuberculosis; Novel treatments; Tuberculosis

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMINOSALICYLIC ACID; BEDAQUILINE; CAPREOMYCIN; CIPROFLOXACIN; CYCLOSERINE; DELAMANID; ETHAMBUTOL; ETHIONAMIDE; GATIFLOXACIN; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; MOXIFLOXACIN; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; OFLOXACIN; POLYPEPTIDE ANTIBIOTIC AGENT; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN; THIORIDAZINE;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL MUTATION; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CROSS RESISTANCE; DRUG EFFECT; DRUG MECHANISM; DRUG RESEARCH; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; EAR INJURY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GLUCOSE HOMEOSTASIS; HUMAN; KIDNEY INJURY; MONOTHERAPY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OPTIC NEURITIS; PATIENT ATTITUDE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT;

ANIMALS; ANTITUBERCULAR AGENTS; DRUG DISCOVERY; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HUMANS; MYCOBACTERIUM TUBERCULOSIS; THIORIDAZINE; TREATMENT FAILURE;

EID: 79959992043     PISSN: 1574891X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489111796064641     Document Type: Article

References (74)

1. WHO. Multidrug and extensively drug-resistant TB (M/XDR-TB) 2010 Global Report on Surveillance and Response: WHO2010.
2. Basu S, Friedland GH, Medlock J, Andrews JR, Shah NS, Gandhi NR, et al. Averting epidemics of extensively drug-resistant tuberculosis. Proc Natl Acad Sci USA 2009;106(18):7672-7.
3. Holtz TH, Cegielski JP. Origin of the term XDR-TB. Eur Respir J 2007; 30(2):396.
4. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368(9547):1575-80.
5. Velayati AA, Farnia P, Masjedi MR, Ibrahim TA, Tabarsi P, Haroun RZ, et al. Totally drug-resistant tuberculosis strains: Evidence of adaptation at the cellular level. Eur Respir J 2009; 34(5):1202-3.
6. The worldwide epidemic of multidrug-resistant tuberculosis. Lancet Infect Dis [Editorial] 2011; 11(5): 333.
7. Migliori GB, Dheda K, Centis R, Mwaba P, Bates M, O'Grady J, et al. Review of multidrug-resistant and extensively drug-resistant TB: global perspectives with a focus on sub-Saharan Africa. Trop Med Int Health. 2010 Jun 10.
8. WHO. Guidelines for the programmatic management of drugresistant tuberculosis Emergency Update 2008 2008.
9. Blower SM, Chou T. Modeling the emergence of the 'hot zones': tuberculosis and the amplification dynamics of drug resistance. Nat Med. [Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S.]. 2004 Oct;10(10):1111-6.
10. Tang S, Zhang Q, Yu J, Liu Y, Sha W, Sun H, et al. Extensively drug-resistant tuberculosis, China. Emerg Infect Dis. [Letter Research Support, Non-U.S. Gov't]. 2011 Mar;17(3):558-60.
11. James P, Gupta R, Christopher DJ, Thankagunam B, Veeraraghavan B. MDR- and XDR-TB among suspected drugresistant TB patients in a tertiary care hospital in India. Clin Respir J 2011; 5(1):19-25.
12. Banu S, Hossain A, Uddin MK, Uddin MR, Ahmed T, Khatun R, et al. Pulmonary tuberculosis and drug resistance in Dhaka central jail, the largest prison in Bangladesh. PLoS One 2010; 5(5):e10759.
13. Nathanson E, Nunn P, Uplekar M, Floyd K, Jaramillo E, Lonnroth K, et al. MDR tuberculosis-critical steps for prevention and control. N Engl J Med 2010; 363(11):1050-8.
14. Gillespie SH. Evolution of drug resistance in Mycobacterium tuberculosis: Clinical and molecular perspective. Antimicrob Agents Chemother 2002; 46(2):267-74.
15. Takiff HE, Salazar L, Guerrero C, Philipp W, Huang WM, Kreiswirth B, et al. Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob Agents Chemother 1994; 38(4): 773-80.
16. David HL. Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis. Appl Microbiol 1970; 20(5): 810-4.
17. Zhang Y, Yew WW. Mechanisms of drug resistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2009; 13(11):1320-30.
18. Shimao T. Drug resistance in tuberculosis control. Tubercle. 1987 Jun;68(2 Suppl):5-18.
19. Mitchison DA. How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. Int J Tuberc Lung Dis 1998; 2(1): 10-5.
20. Lipsitch M, Levin BR. Population dynamics of tuberculosis treatment: Mathematical models of the roles of non-compliance and bacterial heterogeneity in the evolution of drug resistance. Int J Tuberc Lung Dis 1998; 2(3):187-99.
21. Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis. Hong Kong Chest Service/British Medical Research Council. Am Rev Respir Dis. [Clinical Trial Comparative Study Randomized Controlled Trial]. 1987 Dec;136(6):1339-42.
22. Wells CD, Cegielski JP, Nelson LJ, Laserson KF, Holtz TH, Finlay A, et al. HIV infection and multidrug-resistant tuberculosis: The perfect storm. J Infect Dis 2007;196 (Suppl 1): S86-107.
23. Udwadia ZF, Pinto LM, Uplekar MW. Tuberculosis management by private practitioners in Mumbai, India: Has anything changed in two decades? PLoS One 2010; 5(8):e12023.
24. Ginsburg AS, Sun R, Calamita H, Scott CP, Bishai WR, Grosset JH. Emergence of fluoroquinolone resistance in Mycobacterium tuberculosis during continuously dosed moxifloxacin monotherapy in a mouse model. Antimicrob Agents Chemother 2005; 49(9): 3977-9.
25. Ginsburg AS, Woolwine SC, Hooper N, Benjamin WH, Jr., Bishai WR, Dorman SE, et al. The rapid development of fluoroquinolone resistance in M. tuberculosis. N Engl J Med 2003; 349(20): 1977-8.
26. Jacobson KR, Tierney DB, Jeon CY, Mitnick CD, Murray MB. Treatment outcomes among patients with extensively drug-resistant tuberculosis: Systematic review and meta-analysis. Clin Infect Dis. 2010; 51(1): 6-14.
27. Dheda K, Shean K, Badri M. Extensively drug-resistant tuberculosis. N Engl J Med 2008; 359(22): 2390.
28. Dheda K, Shean K, Zumla A, Badri M, Streicher EM, Page-Shipp L, et al. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: A retrospective cohort study. Lancet 2010; 375(9728): 1798-807.
29. Mitnick CD, Shin SS, Seung KJ, Rich ML, Atwood SS, Furin JJ, et al. Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med 2008; 359(6): 563-74.
30. Jacobson KR, Tierney DB, Jeon CY, Mitnick CD, Murray MB. Treatment outcomes among patients with extensively drug-resistant tuberculosis: Systematic review and meta-analysis. Clin Infect Dis 2010; 51(1): 6-14.
31. Caminero JA, Sotgiu G, Zumla A, Migliori GB. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis 2010;10(9): 621-9.
32. Calver AD, Falmer AA, Murray M, Strauss OJ, Streicher EM, Hanekom M, et al. Emergence of increased resistance and extensively drug-resistant tuberculosis despite treatment adherence, South Africa. Emerg Infect Dis 2010;16(2): 264-71.
33. Bonilla CA, Crossa A, Jave HO, Mitnick CD, Jamanca RB, Herrera C, et al. Management of extensively drug-resistant tuberculosis in Peru: cure is possible. PLoS One 2008; 3(8): e2957.
34. Seung KJ, Omatayo DB, Keshavjee S, Furin JJ, Farmer PE, Satti H. Early outcomes of MDR-TB treatment in a high HIV-prevalence setting in Southern Africa. PLoSOne 2009; 4(9): e7186.
35. Thomas A. Management of multidrug resistance tuberculosis in the field: Tuberculosis Research Centre Experience. WHO India; 2010 [updated 2010/07/19/].
36. National Tuberculosis Research C. The Management of Multidrug resistant Tuberculosis in South Africa. MRC South Africa; 1999 [updated 19 July 2010]; 2nd Ed.
37. Somasundaram S, Paramasivan NC. Susceptibility of Mycobacterium tuberculosis strains to gatifloxacin and moxifloxacin by different methods. Chemotherapy 2006; 52(4): 190-5.
38. Von Groll A, Martin A, Jureen P, Hoffner S, Vandamme P, Portaels F, et al. Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. Antimicrob Agents Chemother 2009; 53(10): 4498-500.
39. Kam KM, Yip CW, Cheung TL, Tang HS, Leung OC, Chan MY. Stepwise decrease in moxifloxacin susceptibility amongst clinical isolates of multidrug-resistant Mycobacterium tuberculosis: Correlation with ofloxacin susceptibility. Microb Drug Resist 2006 Spring; 12(1):7-11.
40. Ginsberg AM. Tuberculosis drug development: Progress, challenges, and the road ahead. Tuberculosis 2010; 90(3): 162-7.
41. Lougheed KE, Taylor DL, Osborne SA, Bryans JS, Buxton RS. New anti-tuberculosis agents amongst known drugs. Tuberculosis 2009; 89(5): 364-70.
42. Ahmad S, Mokaddas E. Recent advances in the diagnosis and treatment of multidrug-resistant tuberculosis. Respirat Med 2009; 103(12): 1777-90.
43. Chiang CY, Centis R, Migliori GB. Drug-resistant tuberculosis: Past, present, future. Respirology 2010; 15(3): 413-32.
44. Yew WW, Leung CC. Management of multidrug-resistant tuberculosis: Update 2007. Respirology 2008;13(1): 21-46.
45. Rivers EC, Mancera RL. New anti-tuberculosis drugs with novel mechanisms of action. Curr Medic Chem 2008;15(19):1956-67.
46. London UC. Controlled comparison of two moxifloxacin containing treatment shortening regimens in pulmonary tuberculosis (REMoxTB). National Library of Medicine (US); 2009 [updated April 12 2011; cited 2011 May 09]; Available from: http://clinicaltrials.gov/ct2/show/NCT00864383?term=moxifloxacin+tuberculosis&rank=1.
47. Developpement IdRpl. A controlled trial of a 4-month quinolonecontaining regimen for the treatment of pulmonary tuberculosis. 2005 [updated 20 Sept 2005; cited 2011 May 9]; Available from: http://clinicaltrials.gov/ct2/show/NCT00216385?term=gatifloxacin+tuberculosis&rank=2.
48. Van Deun A, Maug AK, Salim MA, Das PK, Sarker MR, Daru P, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010;182(5): 684-92.
49. Wang F, Langley R, Gulten G, Dover LG, Besra GS, Jacobs WR, Jr., et al. Mechanism of thioamide drug action against tuberculosis and leprosy. J Exp Med 2007; 204(1):73-8.
50. Alliance T. TB Alliance Portfolio 2011 [cited 2011 May 9]; Available from: http://www.tballiance.org/downloads/mediakit/TBA_Portfolio_%205.6.2011.pdf.
51. Diacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R, Page-Shipp L, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009; 360(23): 2397-405.
52. Manjunatha UH, Boshoff H, Dowd CS, Zhang L, Albert TJ, Norton JE, et al. Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proc Nat Acad Sci USA 2006;103(2): 431-6.
53. Diacon AH, Dawson R, Hanekom M, Narunsky K, Maritz SJ, Venter A, et al. Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients. AntimicrobAgents Chemother 2010; 54(8): 3402-7.
54. Nuermberger E, Tyagi S, Tasneen R, Williams KN, Almeida D, Rosenthal I, et al. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrobial Agents Chemotherapy 2008; 52(4):1522-4.
55. Opc-67683. Tuberculosis 2008 88(2):132-3.
56. Otsuka Pharmaceutical Development &Commercialization I. Otsuka Pharmaceutical Development & Commercialization, Inc. Bethesda (MD): National Library of Medicine (US); 2008 [updated Aug 18, 2010; cited 2011 3 May]; Available from: http://clinicaltrials.gov/ct2/show/NCT00685360.
57. Sq109. Tuberculosis 2008; 88(2):159-61.
58. Jia L, Tomaszewski JE, Hanrahan C, Coward L, Noker P, Gorman G, et al. Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug. Br J Pharmacol 2005; 144(1): 80-7.
59. Wallis RS, Jakubiec WM, Kumar V, Silvia AM, Paige D, Dimitrova D, et al. Pharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteers. J Infect Dis 2010; 202(5):745- 51.
60. Williams KN, Brickner SJ, Stover CK, Zhu T, Ogden A, Tasneen R, et al. Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis. Amer J Respirat Crit Care Med 2009; 180(4): 371-6.
61. Williams KN, Stover CK, Zhu T, Tasneen R, Tyagi S, Grosset JH, et al. Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model. Antimicrob Agents Chemotherap 2009; 53(4): 1314-9.
62. Disratthakit A, Doi N. In vitro activities of DC-159a, a novel fluoroquinolone, against Mycobacterium species. Antimicrob Agents Chemother 2010; 54(6): 2684-6.
63. van Soolingen D, Hernandez-Pando R, Orozco H, Aguilar D, Magis-Escurra C, Amaral L, et al. The antipsychotic thioridazine shows promising therapeutic activity in a mouse model of multidrug-resistant tuberculosis. PLoS One 2010; 5(9).
64. Amaral L, Boeree MJ, Gillespie SH, Udwadia ZF, van Soolingen D. Thioridazine cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now. Int J Antimicrob Agents 2010; 35(6): 524-6.
65. Abbate E VM, Natiello M, Cufre M, Garcia A, Ambroggi M. Tuberculosis extensamente resistente (XDR-TB) en Argentina: Aspectos destacbles epidemiologicos, bacteriologicos, terapeuticos y evolutivos. Revista Argentinade Medicina Respiratoria 2007; 1:19-25.
66. Amaral L, Molnar J. Therapy Of XDR TB with thioridazine a drug beyond patent protection but eligible for patent as new use. Rec Pat Antiinfect Drug Discov 2010; 5(2):109-14.
67. Munich L-M-Uo. Early Bactericidal Activity (EBA) of SQ109 in Adult Subjects With Pulmonary TB (SQ109EBA). Bethesda (MD): National Library of Medicine (US); 2010 [cited 2011 3 May]; Available from: http://clinicaltrials.gov/ct2/show/NCT01218217?term=SQ109&rank=1.
68. Wallis RS, Jakubiec WM, Kumar V, Silvia AM, Paige D, Dimitrova D, et al. Pharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteers. J Infect Dis 2010; 202(5):745- 51.
69. Gothi D, Joshi JM. Resistant TB: Newer drugs and community approach. Recent Pat Antiinfect Drug Discov 2011; 6(1): 27-37.
70. Woodcock J, Griffin JP, Behrman RE. Development of novel combination therapies. N Engl J Med 2011; 364(11):985-7.
71. Spigelman M, Woosley R, Gheuens J. New initiative speeds tuberculosis drug development: novel drug regimens become possible in years, not decades. Int J Tuberc Lung Dis 2010;14(6):663-4.
72. Sacks LV, Behrman RE. Developing new drugs for the treatment of drug-resistant tuberculosis: A regulatory perspective. Tuberculosis. 2008; 88 (Suppl 1): S93-100.
73. Perrin FM, Lipman MC, McHugh TD, Gillespie SH. Biomarkers of treatment response in clinical trials of novel antituberculosis agents. Lancet Infect Dis 2007; 7(7): 481-90.
74. Davies GR. Early clinical development of anti-tuberculosis drugs: science, statistics and sterilizing activity. Tuberculosis 2010; 90(3): 171-6.